Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
March 21 2024 - 5:30PM
Business Wire
Quanterix Corporation (NASDAQ: QTRX), a leading provider of
ultra-sensitive research products and high-definition diagnostics,
today announced a specific partnership path for laboratories
interested in offering Tau based research and diagnostic testing
services. Quanterix has secured over thirty U.S. patents protecting
our innovative ultra-sensitive research products and
high-definition diagnostics, and we continue to secure additional
patent protection, both in the United States and abroad. Multiple
patents—including U.S. Patent No. 11,275,092—are directed
specifically to our novel approach to measuring Tau protein levels
in biologic samples.
Those interested in building Alzheimer’s disease (AD) testing
infrastructure should contact Quanterix to discuss potential
partnership opportunities, including avenues for receiving a
non-exclusive license to U.S. Patent No. 11,275,092, to measure Tau
protein using Quanterix’s novel technique. As previously announced,
Quanterix has already established collaborations with multiple
health system entities to offer its instruments and assay tests to
aid in the diagnosis and clinical management of individuals with
AD. Those parties are thus already enjoying the benefits of
Quanterix’s novel Tau measuring techniques. Parties currently
measuring Tau protein in relation to a neurological condition in a
research or diagnostic setting on any other platform risk
infringement of Quanterix’s intellectual property.
For over 10 years, Quanterix has invested significant resources
in the development of ultra-sensitive assay tests and enhancing
research and diagnostics through improved accessibility to blood
biomarker tests. We take this investment and efforts to invent and
innovate seriously. With the advent of FDA approval of an AD
therapy, Quanterix is focused on building the global infrastructure
necessary for AD testing by expanding clinical access to
Quanterix’s leading blood biomarker assays. Licensing inquiries can
be directed to licensing@quanterix.com.
In conjunction with this announcement, the Company will host a
conference call on March 25, 2024 at 4:00 p.m. E.T. Click here to
pre-register for the conference call and obtain your dial-in number
and passcode.
Interested investors can also listen to the live webcast from
the Event Details page in the Investors section of the Quanterix
website at http://www.quanterix.com.
About Quanterix From discovery to diagnostics,
Quanterix’s ultrasensitive biomarker detection is fueling
breakthroughs only made possible through its unparalleled
sensitivity and flexibility. The Company’s Simoa® technology has
delivered the gold standard for earlier biomarker detection in
blood, serum or plasma, with the ability to quantify proteins that
are far lower than the Limit of Quantification (LoQ) of
conventional analog methods. Its industry-leading precision
instruments, digital immunoassay technology and CLIA-certified
Accelerator laboratory have supported research that advances
disease understanding and management in neurology, oncology,
immunology, cardiology and infectious disease. Quanterix has been a
trusted partner of the scientific community for nearly two decades,
powering research published in more than 2,700 peer-reviewed
journals. Find additional information about the Billerica,
Massachusetts-based company at https://www.quanterix.com or follow
us on Twitter and LinkedIn.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “may,”
“will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements in this news release are based on Quanterix’s
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Factors that may cause Quanterix’s actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Quanterix’s
filings with the U.S. Securities and Exchange Commission, including
the “Risk Factors” sections contained therein. Except as required
by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321224578/en/
Media: Maya Nimnicht, PAN Communications (510) 334-6273
pan.quanterix@pancomm.com
Investor Relations: Amy Achorn (978) 488-1854
ir@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024